Back to list

Exploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A1chieve study

Mohamed Belhadj a * , Amine Dahaoui b, Henda Jamoussi c and Ahmed Farouqi d

Diabetes Research and Clinical Practice, pages S4 - S14

Published online Aug-2013

Article view:



To evaluate the safety and effectiveness of insulin analogues in patients with type 2 diabetes (T2D) from Morocco, Algeria and Tunisia that formed the Maghrebian cohort of the 24-week, non-interventional A1chieve study.


Patients starting biphasic insulin aspart, insulin detemir and insulin aspart, alone or in combination, were included. The primary outcome was the incidence of serious adverse drug reactions (SADRs), including major hypoglycaemic events. Secondary outcomes included hypoglycaemia, glycated haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), systolic blood pressure (SBP), body weight and lipids. Quality of life (QoL) was evaluated using the EQ-5D questionnaire.


Overall, 3720 patients with a mean age of 58.6 years, body mass index of 27.7 kg/m2 and diabetes duration of 11.5 years were enrolled. Pre-study, insulin-experienced patients had a mean±SD dose of 0.54±0.27 U/kg. In the entire cohort, the mean dose was 0.42±0.27U/kg at baseline, titrated to 0.55±0.30U/kg by Week 24. Twenty-six SADRs were reported during the study. There was a significant decrease in the proportion of patients reporting overall hypoglycaemia from baseline to Week 24 (18.3% to 13.8%, p < 0.0001). The mean HbA1c improved significantly from 9.5±1.8% to 7.9±1.4% (p < 0.001). The mean FPG, PPPG, SBP, total cholesterol and QoL also improved significantly (all p < 0.001), while the mean body weight increased by 0.9±3.9 kg (p < 0.001).


Insulin analogue therapy was well-tolerated and was associated with improved glycaemic control.

Keywords: Type 2 diabetes, Insulin analogues, Maghreb.

Article Outline


  • 1 SV Edelman. Type II diabetes mellitus. Adv Intern Med. 1998;43:449-500
  • 2 International Diabetes Federation. IDF Diabetes Atlas 5th edn. (International Diabetes Federation, Brussels, Belgium, 2011) Accessed on 5 March 2013.
  • 3 K Niswender. Early and aggressive initiation of insulin therapy for type 2 diabetes: What is the evidence?. Clin Diab. 2009;27:60-68
  • 4 M Peyrot, AH Barnett, LF Meneghini, PM Schumm-1raeger. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682-689
  • 5 RR Rubin, M Peyrot, DF Kruger, LB Travis. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ. 2009;35(6):1014-1022
  • 6 SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-1596
  • 7 P Valensi, M Benroubi, V Borzi, J Gumprecht, R Kawamori, J Shaban, et al., IMPROVE Study Group Expert Panel. The IMPROVE study-a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract. 2008;62(11):1809-1819
  • 8 DR Whiting, L Guariguata, C Weil, J Shaw. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311-321
  • 9 N Gupta, P Shah, S Nayyar, A Misra. Childhood Obesity and the Metabolic Syndrome in Developing Countries. Indian J Pediatr. 2013 Jan 20; [Epub ahead of print].
  • 10 M Belhadj, R Malek, A Boudiba, E Lezzar, D Roula, F Sekkal, et al. DiabCare Algérie. Médecine des maladies Métaboliques. 2010;4(1):1-5
  • 11 L Brunetti, J Kalabalik. Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies. P T. 2012;37(12):687-696
  • 12 I Hartman. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res. 2008;6(2):54-67
  • 13 K Hermansen, M Colombo, H Storgaard, A Østergaard, K Kølendorf, S Madsbad. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care. 2002;25(5):883-888
  • 14 S Shah, M Benroubi, V Borzi, J Gumprecht, R Kawamori, J Shaban, et al., IMPROVE Study Group Expert Panel. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study. Int J Clin Pract. 2009;63(4):574-582
  • 15 LF Meneghini, KH Rosenberg, C Koenen, MJ Merilainen, HJ Lüddeke. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9(3):418-427
  • 16 P Home, NE Naggar, M Khamseh, G Gonzalez-Galvez, C Shen, P Chakkarwar, et al. An observational non-interventional study of patients with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Res Clin Pract. 2011;94:352-363
  • 17 NK Naggar, P Soewondo, ME Khamseh, JW Chen, J Haddad. Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: Results from the A(1)chieve study. Diabetes Res Clin Pract. 2012;98(3):408-413
  • 18 A Dornhorst, HJ Lüddeke, C Koenen, M Meriläinen, A King, A Robinson, et al., PREDICTIVE Study Group. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE. Diabetes Obes Metab. 2008;10(1):75-81
  • 19 P Hollander, J Cooper, J Bregnhøj, CB Pedersen. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30(11):1976-1987
  • 20 RR Rubin, M Peyrot. Quality of life and diabetes. Diabetes Metab Res Rev. 1999;15(3):205-218


a Internal Medicine Department, EHU Oran, Algeria Internal Medicine Department, EHU Oran, Algeria

b Medical Department, Novo Nordisk, Algeria Medical Department, Novo Nordisk, Algeria

c Département A, Institut National de Nutrition, Tunis, Tunisia Département A, Institut National de Nutrition, Tunis, Tunisia

d Diabetes, Endocrinology and Nutrition Department, Ibn Rochd University Hospital, Casablanca, Morocco Diabetes, Endocrinology and Nutrition Department, Ibn Rochd University Hospital, Casablanca, Morocco

* Corresponding author at: Internal Medicine Department, Etablissement Hospitalier-Universitaire, Oran, Algeria

Back to list